Navigation Links
Once-Promising Heart Failure Drug Fails in Trial
Date:10/7/2010

By Amanda Gardner
HealthDay Reporter

WEDNESDAY, Oct. 6 (HealthDay News) -- A new experimental drug for treating patients who have acute heart failure plus kidney failure did not show any overall benefit, indicating that the future of this particular drug, called rolofylline, is over.

"I think this is the end of the story for this drug," said Dr. Barry Massie, lead author of a study appearing in the Oct. 7 issue of the New England Journal of Medicine. "There was a very promising pilot trial but these results . . . were neutral. I am disappointed," he said.

The results were presented last year at the European Society of Cardiology meeting. Shortly before that, drug company Merck, which has been developing the medicine and which funded this study, announced that it would not be filing for U.S. Food and Drug Administration approval for rolofylline.

Rolofylline is known as an A1-receptor antagonist and is intended to make diuretics work more effectively.

Other drugs in the same class of medications that were developed by other companies have met with similarly disappointing results after promising early results, said Massie, who is chief of the cardiology division at the San Francisco VA Medical Center and professor of medicine at the University of California, San Francisco.

He explained that kidney problems are a major complication of heart failure and "those patients who develop renal [kidney] failure in the course of treatment have a much higher hospital admission and death rate."

This may be at least partly because patients are taken off of certain cardiac medications in order to improve kidney function.

"This is sort of a perfect storm," Massie said.

For this study, just over 2,000 patients who had been hospitalized for acute heart failure and kidney problems were randomly assigned to receive a placebo or 30 milligrams of rolofylline daily intravenously. Treatment lasted for up to three days.

Rolofylline did not prolong survival or improve heart failure or kidney function when compared with the placebo.

And in contrast to the placebo group, some patients taking rolofylline had seizures, indicating that the drug was able to cross the blood-brain barrier. Seizures are a potential side effect for this class of drugs.

"[We] had hoped that the drug didn't cross the blood-brain barrier," Massie said.

One expert was similarly disappointed with the study results.

"Rolofylline certainly does not seem to have benefit in terms of risk of mortality (or death) and hospital readmission," noted Dr. Tara Narula, a cardiologist with Lenox Hill Hospital in New York City. "At this point, unfortunately, we're left with what we have in our arsenal, which we've [already] had for many years."

That includes IV loop diuretics, ACE inhibitors and beta blockers, she said.

More information

There's more on heart failure at the American Heart Association.

SOURCES: Barry M. Massie, M.D., chief, cardiology division, San Francisco VA Medical Center and professor of medicine, University of California, San Francisco; Tara Narula, M.D., cardiologist, Lenox Hill Hospital, New York City; Oct. 7, 2010, New England Journal of Medicine


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Workplace Noise Tied to Heart Disease Risk
2. Testosterone Could Boost Health of Heart Failure Patients
3. Dental Care Linked to Heart Health in Older Women
4. Heart, kidney, diabetes and cancer MEP groups league against chronic disease to seek European commitment
5. Women who get dental care have lower risk of heart disease, says study
6. WUSTL awarded $18 million to treat heart, lungs with nanotechnology
7. Researchers use CT to predict heart disease
8. ESC announces new initiatives for workplace heart health programs
9. Disparities in heart attack treatment may begin in the emergency room
10. Molecular playbook for halting heart failure risk factor uncovered
11. Surgery May Be Best for Irregular Heartbeat in Young
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Once-Promising Heart Failure Drug Fails in Trial
(Date:4/24/2017)... ... April 24, 2017 , ... Pitavastatin, a relatively new ... is not known to have significant interactions with antiretroviral therapy (ART). Among ... levels and dampen inflammation in the bloodstream. , While lowering cholesterol and dampening ...
(Date:4/24/2017)... ... April 24, 2017 , ... Donna Parker, L. Ac. ... has not found any of them to be very practical. She wanted to write ... easily make changes in their health. It prompted her in writing “ A Clear ...
(Date:4/24/2017)... , ... April 24, 2017 , ... “The Saint with ... with Trin, and Omega Station” is the creation of published author, Chris Jackson. ... Metroplex where he works in the Dallas Independent School District teaching English. He is ...
(Date:4/24/2017)... ... April 24, 2017 , ... Anaconda BioMed, a pre-clinical stage ... the treatment of Acute Ischemic Stroke (AIS), today announced it has appointed Creganna ... advances towards regulatory and clinical phases. , "This is another important step for ...
(Date:4/22/2017)... Carolina (PRWEB) , ... April 22, 2017 , ... Ecommerce ... the United States estimated to be $394.9 billion. The consequences of rapid innovation ... inevitably demolishes) the limits of technology, it is every business and individual’s job to ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... DALLAS , April 19, 2017 /PRNewswire/ ... that the first patients in Nashville ... in the Lower Esophageal Sphincter Stimulation for GERD (LESS ... device designed to provide long-term reflux control by restoring ... GERD affects nearly 65 million people in ...
(Date:4/19/2017)... April 19, 2017 ... immune response in pets such as canine, avian ... of various types such as Attenuated Live Vaccines, ... DNA Vaccines and Recombinant Vaccines. Attenuated live vaccines ... or bacteria, which have been weakend under laboratory ...
(Date:4/19/2017)... 19, 2017  SARES•REGIS Group leased the first ... at Conejo Spectrum Business Park in ... Biotherapeutics, Inc. , a biopharmaceutical company developing meaningful ... that have been underserved by scientific innovation, with ... cancer, autoimmune and infectious disease. Before ...
Breaking Medicine Technology: